Dramatic advances in the fields of biochemistry, cell and molecular biology, genetics, biomedical engineering and materials science have given rise to the remarkable new cross-disciplinary field of tissue engineering. Tissue engineering uses synthetic or naturally derived, engineered biomaterials to replace damaged or defective tissues, such as bone, skin, and even organs.
In a newly published and ground-breaking text, senior academics from Swansea University have concluded that membrane characterisation is essential for the continued growth in the industrial application of membranes.
A new study of bone formation from stem cells seeded on 3D-printed bioactive scaffolds combined with different mineral additives showed that some of the scaffold mineral composites induced bone-forming activity better than others.
Instead of running tests on live kidneys, researchers at Binghamton, University State University of New York have developed a model kidney for working out the kinks in medicines and treatments.
Methicillin-resistant Staphylococcus aureus (MRSA) infections are caused by a type of staph bacteria that has become resistant to the antibiotics used to treat ordinary staph infections.
In patients who suffered acute orthopedic injuries, two proposed biomarkers for mild traumatic brain injury (mTBI) were not able to distinguish between patients who did or did not have mTBI.
Researchers have grown heart tissue by seeding a mix of human cells onto a 1-micron-resolution scaffold made with a 3-D printer.
Advanced engineering of a mini-intronic plasmid (MIP) system designed to carry a therapeutic gene can significantly enhance the expression of the transgene delivered using an adeno-associated viral (AAV) vector.
Medical implants like stents, catheters and tubing introduce risk for blood clotting and infection - a perpetual problem for many patients.
A process using human stem cells can generate the cells that cover the external surface of a human heart -- epicardium cells -- according to a multidisciplinary team of researchers.
A new method of stimulating the renewal of living stem cells in tooth pulp using an Alzheimer's drug has been discovered by a team of researchers at King's College London.
To understand the molecular mechanisms involved in the interaction of bone with orthopedic implants comprised of novel biomaterials, researchers have made a mouse model in which they can assess early tissue responses to surfaces such as bioactive glass.
A chance meeting between a spider expert and a chemist has led to the development of antibiotic synthetic spider silk.
Liver-directed gene therapy delivered using adeno-associated viral (AAV) vectors to treat diseases such as hemophilia have advanced into human testing.
Many gene therapy-based approaches are in development to combat genetic and other causes of blindness and vision loss, and much can be learned about the safety and effectiveness of these promising new therapies by studying them first in non-human primates before initiating clinical trials, as shown by the results of a study published in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.
Scientists from the Tomsk Polytechnic University's Laboratory of Novel Dosage are developing a technology to control mesenchymal stem cells of patients.
A new study has revealed a technology how to cover biodegradable implants with a human skeleton similar mineral.
Recent evidence from animal models suggests a role for specific types of intestinal bacteria in the development of colorectal cancer (CRC).
Polymerization by chemical vapor deposition (CVD) is a simple method for modifying surfaces by which topologically challenging substrates can be evenly coated with polymers.
Chitosan, a biomaterial derived from the chitin shells of crustaceans and insects, has already been developed by scientists at Harvard's Wyss Institute for Biologically Inspired Engineering into an environmentally-friendly and fully biodegradable substitute for plastic.
Enabling the arrival of advanced therapies from pre-clinical stages to industrial production and clinical application: this is the objective of ADVANCECAT project, led by the University of Barcelona and Ferrer, and build up by eighteen entities of the health field in which there are two universities, twelve biomedical research institutes or private foundations, and four companies.